ResMed (RMD) is trading lower in the latest session after the company released fiscal third-quarter 2026 results for the period ended March 31, 2026. The decline is notable because the print showed strong year-over-year growth and expanding margins, but the market’s reaction suggests expectations were elevated into the release and attention quickly shifted to the quality of the beat and cost trends. (investor.resmed.com)

For fiscal Q3 2026, ResMed reported revenue of $1.431 billion, up 11% year over year (8% on a constant-currency basis). GAAP gross margin rose to 62.2% (up 290 bps), and non-GAAP diluted EPS increased to $2.86 (up 21%), with operating cash flow of $554 million in the quarter. (investor.resmed.com)

Even with margin expansion, the release flagged higher operating expense lines and other items that can temper enthusiasm after a strong run into earnings. In the quarter, SG&A increased materially year over year, and the company also recorded acquisition and portfolio review-related expenses; investors also noted balance-sheet line items such as a rise in short-term debt versus the prior-year period. The combination can make a “beat” feel less clean, prompting a sell-the-news reaction. (stocktitan.net)

ResMed returned $262 million to shareholders during the quarter through $175 million of share repurchases and $87 million of dividends, and it declared a $0.60 quarterly cash dividend with a May 14, 2026 record date and June 18, 2026 payment date. Next attention centers on management commentary from the earnings call, including updates on demand trends, cost discipline, and any revisions to expectations for the remainder of fiscal 2026. (investor.resmed.com)